Reuters – BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.
The Phase 3 clinical trial is expected to include about 200 patients and will be conducted at six ALS clinical sites in the United States, Israel-based BrainStorm said on Monday.
The company is developing a treatment made from adult stem cells for patients with ALS, a neuro-degenerative disease. The treatment, called NurOwn, has been administered to 75 ALS patients in clinical trials in the United States and Israel.
Read more at Reuters.